PTC Therapeutics
PTCT
#3295
Rank
S$4.74 B
Marketcap
$61.54
Share price
-0.46%
Change (1 day)
63.39%
Change (1 year)

P/E ratio for PTC Therapeutics (PTCT)

P/E ratio as of December 2024 (TTM): -5.24

According to PTC Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.24277. At the end of 2022 the company had a P/E ratio of -4.90.

P/E ratio history for PTC Therapeutics from 2013 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-4.90-8.6%
2021-5.36-41.41%
2020-9.15-14.84%
2019-10.7-15.78%
2018-12.859.1%
2017-8.02206.51%
2016-2.62-59.14%
2015-6.40-60.3%
2014-16.1166.28%
2013-6.06

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
31.2-694.77%๐Ÿ‡บ๐Ÿ‡ธ USA
-15.6 196.95%๐Ÿ‡บ๐Ÿ‡ธ USA
-0.7650-85.41%๐Ÿ‡บ๐Ÿ‡ธ USA
-10.1 92.89%๐Ÿ‡บ๐Ÿ‡ธ USA
-11.4 116.50%๐Ÿ‡บ๐Ÿ‡ธ USA
26.3-601.58%๐Ÿ‡จ๐Ÿ‡ญ Switzerland

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.